MedTrace Logo

Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma

NCT07529808 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 164

Last updated 2026-05-08

No results posted yet for this study

Summary

This study is looking at how safe BHB810 is in adults with gastric and gastroesophageal adenocarcinoma (GEJ). The purpose of this study is also to look at: how well the study drug works, how the study drug moves into, through, and out of the body, and how your body reacts to the study drug. Participants will get an IV infusion of BHB810 every 2 weeks while on study treatment.

Conditions

  • Gastric Cancer
  • Gastric Adenocarcinoma
  • Gastric (Stomach) Cancer
  • Gastroesophageal Adenocarcinoma
  • Gastroesophageal Cancer (GC)
  • Gastroesophageal Junction (GEJ) Adenocarcinoma
  • Gastroesophageal Junction (GEJ) Cancer
  • Gastrointestinal Cancer Metastatic
  • Gastrointestinal Adenocarcinoma
  • Gastrointestinal Cancers
  • Colorectal (Colon or Rectal) Cancer
  • Pancreatic Cancer
  • CDH17-positive Advanced Solid Tumors
  • Advanced Gastric Cancer

Interventions

DRUG

BHB810

Every 2 weeks IV administration

Sponsors & Collaborators

  • BigHat Biosciences, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2028-12-31
Completion
2028-12-31
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07529808 on ClinicalTrials.gov